申请人:Merck & Co., Inc.
公开号:US05750549A1
公开(公告)日:1998-05-12
The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.
本发明涉及由结构式I表示的某些新化合物:##STR1##或其药学上可接受的盐,其中R.sup.3、R.sup.6、R.sup.7、R.sup.8、R.sup.11、R.sup.12、R.sup.13、A、Q、W、X、Y、Z和n在此处定义。本发明还涉及包含这些新化合物作为活性成分的药物配方,以及在治疗某些疾病中使用这些新化合物及其配方。本发明的化合物是催吐肽受体拮抗剂,可用于治疗炎症性疾病、疼痛或偏头痛、哮喘和呕吐。